Showing 3391-3400 of 5621 results for "".
- EssilorLuxottica to Acquire Ophthalmic Lens Materials Division of PUcorehttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmic-lens-materials-division-of-pucore/2482895/EssilorLuxottica has signed an agreement with the South Korean-based PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of monomers used in the production of high index ophthalmic lenses. The assets acquired by EssilorLuxottica inclu
- Topcon Partners with OKKO Health to Advance Home-Based Vision Monitoring and Patient Engagementhttps://modernod.com/news/topcon-partners-with-okko-health-to-advance-home-based-vision-monitoring-and-patient-engagement/2482894/Topcon Healthcare announced an investment in OKKO Health, a UK-based provider of vision testing software. While financial terms of the deal were not disclosed, the investment positions Topcon as the lead in OKKO Health’s seed funding round.
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons
- Harrow Enters into Commercialization Agreement with Samsung Bioepis for Biosimilars Portfolio in the UShttps://modernod.com/news/harrow-enters-into-commercialization-agreement-with-samsung-bioepis-for-ophthalmology-biosimilars-portfolio-in-the-us/2482890/Harrow announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, which includes Byooviz (ranibizumab-nuna), an FDA-ap
- Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and Unlicensed Territorieshttps://modernod.com/news/nicox-and-kowa-sign-agreement-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories/2482889/Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excludin
- EyeDura's Sustained-Release Eye Drop Technology Wins Industry Honorshttps://modernod.com/news/eyeduras-sustained-release-eye-drop-technology-wins-industry-honors/2482886/EyeDura Therapeutics, developer of preservative-free sustained release ophthalmic therapies, announced it received top recognition at two major industry forums among a field of ophthalmic startup companies. EyeDura won 'The Winning Pitch' challeng
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce
- Wayne Caulder Joins Bausch + Lomb as Vice President and General Manager, Surgical, UShttps://modernod.com/news/wayne-caulder-joins-bausch-lomb-as-vice-president-and-general-manager-surgical-us/2482881/Wayne Caulder has joined Bausch + Lomb as vice president and general manager, Surgical, US and Canada. Mr. Caulder brings more than 30 years of experience in the eye health industry across multiple therapeutic categories, including cataract and refractive surgery, retina and r
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- Bausch + Lomb Launches Dry Eye Education Campaignhttps://modernod.com/news/bausch-lomb-launches-dry-eye-education-campaign/2482872/Bausch + Lomb announced the launch of “Eyes Tell the Story: The Impact of Dry Eye,” a new awareness campaign designed to spotlight the burden of dry eye symptoms through storytelling, photography, and insights from the company’s latest nationw